# (19) World Intellectual Property Organization

International Bureau



(43) International Publication Date 15 April 2004 (15.04.2004)

(10) International Publication Number WO 2004/030615 A2

(51) International Patent Classification7:

**A61K** 

(21) International Application Number:

PCT/US2003/028547

(22) International Filing Date:

29 September 2003 (29.09.2003)

(25) Filing Language:

**English** 

(26) Publication Language:

**English** 

(30) Priority Data: 60/414,971

2 October 2002 (02.10.2002) US

(71) Applicant (for all designated States except US): GENEN-TECH, INC. [US/US]; 1 DNA Way, South San Francisco, CA 94080-4990 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): WU, Thomas, D. [US/US]; 41 Nevada Street, San Francisco, CA 94110 (US). ZHANG, Zemin [US/US]; 876 Taurus Drive, Foster City, CA 94404 (US). ZHOU, Yan [CN/US]; #111, 525 N Curtis Avenue, Alhambra, CA 91801 (US).

(74) Agents: KRESNAK, Mark T. et al.; c/o Genentech, Inc., MS49, 1 DNA Way, South San Francisco, CA 94080-4990

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, Cl, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

### Published:

without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR

(57) Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.

Application/Control Number: 10/718,834 Page 12

Art Unit: 1647

# APPENDIX

```
RESULT 15
ABM81255
     ABM81255 standard; protein; 1019 AA.
ID
XX
AC
    ABM81255;
XX
DT
     18-NOV-2004 (first entry)
XX
     Tumour-associated antigenic target (TAT) polypeptide PRO81993, SEQ:3235.
DΕ
XX
os
     Homo sapiens.
XX
PN
     WO2004030615-A2.
XX
     15-APR-2004.
PD
XX
     29-SEP-2003; 2003WO-US028547.
PF
XX
PR
     02-OCT-2002; 2002US-0414971P.
XX
PA
     (GETH ) GENENTECH INC.
XX
PΙ
    Wu TD, Zhang Z, Zhou Y;
XX
DR
     WPI; 2004-347921/32.
DR
     N-PSDB; ACN39223.
XX
PT
     New tumor-associated antigenic target polypeptides and nucleic acids,
PT
     useful in preparing a medicament for treating or detecting a
PT
     proliferative disorder, e.g. breast, lung, colorectal, ovarian or
PT
     prostate cancer or tumor.
XX
PS
     Claim 12; SEQ ID NO 3235; 7273pp; English.
XX
CC
     The invention relates to human tumour-associated antigenic target (TAT)
CC
     polypeptides, and their related nucleic acids. The TAT polypeptides are
CC
     overexpressed in cancer tissues compared to normal tissues, and may thus
CC
     serve as effective targets for the diagnosis and treatment of cancer in
CC
     mammals. The invention also relates to nucleic acid and polypeptide
CC
     sequences at least 80% identical to the TAT nucleic acids and
CC
     polypeptides; expression vectors and host cells comprising a TAT nucleic
CC
     acid; an antibody specific for a TAT polypeptide; a peptide or organic
CC
     molecule which binds to a TAT polypeptide; fusion proteins comprising a
CC
     TAT polypeptide; and methods and compositions for the treatment or
CC
     diagnosis of cancer in mammals. TAT polypeptides, nucleic acids,
CC
     antibodies, antagonists, binding molecules and compositions are useful
CC
     for diagnosing or treating a cell proliferative disorder associated with
CC
     increased TAT expression, particularly cancers such as breast cancer,
CC
     colorectal cancer, lung cancer, ovarian cancer, liver cancer, bladder
CC
     cancer, pancreatic cancer, cervical cancer, cancers of the central
CC
     nervous system, melanoma and leukaemia. TAT nucleic acids may further be
CC
     used as hybridisation probes, in chromosome and gene mapping, in
```

Application/Control Number: 10/718,834 Page 13

Art Unit: 1647

```
CC
   chromosome identification and in gene therapy. The present sequence
CC
   represents a TAT polypeptide of the invention
XX
SO
   Sequence 1019 AA;
                   85.2%;
                         Score 5152; DB 8; Length 1019;
 Query Match
                   99.9%;
                         Pred. No. 0;
 Best Local Similarity
                          Mismatches
                                         Indels
 Matches 992; Conservative
                        1;
                                      0;
                                                   Gaps
0;
       170 AAOELSOEIKAFLTGVDPILGHQLSAREHARCGLLLLRSLPPARAAVLDHLRGVFDESVR 229
Qу
          27 SAQELSQEIKAFLTGVDPILGHQLSAREHARCGLLLLRSLPPARAAVLDHLRGVFDESVR 86
Db
       230 AHLAALDETPVAGPPHLRPPPPSHVPAGGPGLEDVVOEVOOVLSEFIRANPKAWAPVISA 289
Qу
          87 AHLAALDETPVAGPPHLRPPPPSHVPAGGPGLEDVVQEVQQVLSEFIRANPKAWAPVISA 146
Db
       290 WSIDLMGQLSSTYSGQHQRVPHATGALNELLQLWMGCRATRTLMDIYVQCLSALIGSCPD 349
Qy
          147 WSIDLMGOLSSTYSGOHORVPHATGALNELLQLWMGCRATRTLMDIYVQCLSALIGSCPD 206
Db
       350 ACVDALLDTSVQHSPHFDWVVAHIGSSFPGTIISRVLSCGLKDFCVHGGAGGGAGSSGGS 409
Qу
          207 ACVDALLDTSVQHSPHFDWVVAHIGSSFPGTIISRVLSCGLKDFCVHGGAGGGAGSSGGS 266
Db
       410 SSQTPSTDPFPGSPAIPAEKRVPKIASVVGILGHLASRHGDSIRRELLRMFHDSLAGGSG 469
Qy
          267 SSQTPSTDPFPGSPAIPAEKRVPKIASVVGILGHLASRHGDSIRRELLRMFHDSLAGGSG 326
Db
       470 GRSGDPSLQATVPFLLQLAVMSPALLGTVSGELVDCLKPPAVLSQLQQHLQGFPREELDN 529
Qу
          327 GRSGDPSLOATVPFLLQLAVMSPALLGTVSGELVDCLKPPAVLSQLQQHLQGFPREELDN 386
Db
       530 MLNLAVHLVSOASGAGAYRLLQFLVDTAMPASVITTQGLAVPDTVREACDRLIQLLLLHL 589
Qу
          387 MLNLAVHLVSQASGAGAYRLLQFLVDTAMPASVITTQGLAVPDTVREACDRLIQLLLLHL 446
Db
       590 OKLVHHRGGSPGEGVLGPPPPPRLVPFLDALKNHVGELCGETLRLERKRFLWQHQLLGLL 649
Qу
          447 QKLVHHRGGSPGEGVLGPPPPPRLVPFLDALKNHVGELCGETLRLERKRFLWQHQLLGLL 506
Db
       650 SVYTRPSCGPEALGHLLSRARSPEELSLATOLYAGLVVSLSGLLPLAFRSCLARVHAGTL 709
Qу
          507 SVYTRPSCGPEALGHLLSRARSPEELSLATQLYAGLVVSLSGLLPLAFRSCLARVHAGTL 566
Db
       710 OPPFTARFLRNLALLVGWEOOGGEGPAALGAHFGESASAHLSDLAPLLLHPEEEVAEAAA 769
Qy
          567 QPPFTARFLRNLALLVGWEQQGGEGPAALGAHFGESASAHLSDLAPLLLHPEEEVAEAAA 626
Db
       770 SLLAICPFPSEALSPSQLLGLVRAGVHRFFASLRLHGPPGVASACQLLTRLSQTSPAGLK 829
Qу
          627 SLLAICPFPSEALSPSQLLGLVRAGVHRFFASLRLHGPPGVASACQLLTRLSQTSPAGLK 686
Db
```

Application/Control Number: 10/718,834 Page 14

Art Unit: 1647

QУ	830	AVLQLLVEGALHRGNTELFGGQVDGDNETLSVVSASLASASLLDTNRRHTAAVPGPGGIW 889
Db	687	AVLQLLVEGALHRGNTELFGGQVDGDNETLSVVSASLASASLLDTNRRHTAAVPGPGGIW 746
Qу	890	SVFHAGVIGRGLKPPKFVQSRNQQEVIYNTQSLLSLLVHCCSAPGGTECGECWGAPILSP 949
Db	747	SVFHAGVIGRGLKPPKFVQSRNQQEVIYNTQSLLSLLVHCCSAPGGTECGECWGAPILSP 806
Qу	950	EAAKAVAVTLVESVCPDAAGAELAWPPEEHARATVERDLRIGRRFREQPLLFELLKLVAA1009
Db	807	EAAKAVAVTLVESVCPDAAGAELAWPPEEHARATVERDLRIGRRFREQPLLFELLKLVAA 866
QУ	1010	APPALCYCSVLLRGLLAALLGHWEASRHPDTTHSPWHLEASCTLVAVMAEGSLLPPALGN1069
Db	867	APPALCYCSVLLRGLLAALLGHWEASRHPDTTHSPWHLEASCTLVAVMAEGSLLPPALGN 926
QУ	1070	MHEVFSQLAPFEVRLLLLSVWGFLREHGPLPQKFIFQSERGRFIRDFSREGGGEGGPHLA1129
Db	927	MHEVFSQLAPFEVRLLLLSVWGFLREHGPLPQKFIFQSERGRFIRDFSREGGGEGGPHLA 986
QУ	1130	VLHSVLHRNIDRLGLFSGRFQAPSPSTLLRQGT 1162
Db	987	VLHSVLHRNIDRLGLFSGRFQAPSPSTLLRQGT 1019

WO 2004/030615 PCT/US2003/028547

# 3508/6881 FIGURE 3235

MSALCDPPGAPGPPGPAPATHGPAPLSAQELSQEIKAFLTGVDPILGHQLSAREHARCGLLLRSLPPARAAVLD HLRGVFDESVRAHLAALDETPVAGPPHLRPPPPSHVPAGGPGLEDVVQEVQQVLSEFIRANPKAWAPVISAWSID LMGQLSSTYSGQHQRVPHATGALNELLQLWMGCRATRTLMDIYVQCLSALIGSCPDACVDALLDTSVQHSPHFDW VVAHIGSSFPGTIISRVLSCGLKDFCVHGGAGGAGSSGGSSSQTPSTDPFPGSPAIPAEKRVPKIASVVGILGH LASRHGDSIRRELLRMFHDSLAGGSGGRSGDPSLQATVPFLLQLAVMSPALLGTVSGELVDCLKPPAVLSQLQQH LQGFPREELDNMLNLAVHLVSQASGAGAYRLLQFLVDTAMPASVITTQGLAVPDTVREACDRLIQLLLLHLQKLV HHRGGSPGEGVLGPPPPPRLVPFLDALKNHVGELCGETLRLERKRFLWQHQLLGLLSVYTRPSCGPEALGHLLSR ARSPEELSLATQLYAGLVVSLSGLLPLAFRSCLARVHAGTLQPPFTARFLRNLALLVGWEQQGGEGPAALGAHFG ESASAHLSDLAPLLHPEEEVAEAAASLLAICPFPSEALSPSQLLGLVRAGVHRFFASLRLHGPPGVASACQLLT RLSQTSPAGLKAVLQLLVEGALHRGNTELFGGQVDGDNETLSVVSASLASASLLDTNRRHTAAVPGPGGIWSVFH AGVIGRGLKPPKFVQSRNQQEVIYNTQSLLSLLVHCCSAPGGTECGECWGAPILSPEAAKAVAVTLVESVCPDAA GAELAWPPEEHARATVERDLRIGRRFREQPLLFELLKLVAAAPPALCYCSVLLRGLLAALLGHWEASRHPDTTHS PWHLEASCTLVAVMAEGSLLPPALGNMHEVFSQLAPFEVRLLLLSVWGFLREHGPLPQKFIFQSERGRFIRDFSR EGGGEGGPHLAVLHSVLHRNIDRLGLFSGRFQAPSPSTLLROGT

10/10/06, EAST Version: 2.1.0.14